MHRA, TGA Give Clean Review To Ranbaxy’s Paonta Sahib Plant, But U.S. FDA Holds The Key
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Even as U.S. FDA tightened its scrutiny of Ranbaxy's manufacturing plant at Paonta Sahib in India on alleged charges of falsification of data, two of the world's largest drug regulators - UK's Medicines and Healthcare Products Regulatory Agency and Australia's Therapeutic Goods Administration gave the plant a clean review